Pharmacokinetic and Residual Time Study of Oxolinic Acid in the Sea Fish Trachinotus blochii and Lates calcarifer / 歐索林酸在海水魚黃長鰭黃鱲鰺與金目鱸之藥物動力學及殘留試驗

碩士 / 國立臺灣大學 / 獸醫學研究所 / 99 / The sea water used for fish culture instead of fresh water in the west-south sea shore of Taiwan was very common. Owing to the land fish pond was not wide, the aquaculture in high density caused the high risks for suffering several diseases. In order to prevent the diseases of fish, not only improving the cultivating environments and techniques, but also tried to use various chemical therapy drugs in clinical use. Taiwan is located in the subtropical area, the water temperature was so often warm that the fish always suffered from viral, bacterial infected diseases, others such as parasite, protozoa, alga and mould were also infestation in fish.
An experimental trial was performed to determine the half life of oxolinic acid in sea fish Trachinotus blochii and Lates calcarifer of pharmacokinetic and residue studies. A single dose pharmacokinetic study of oxolinic acid was applied by oral administration at the dose of 60 mg/kg b.w./day. A high performance liquid chromatographic method based on fluorescence detection was developed for determination of oxolinic acid in fish blood, tissue samples. Oxolinic acid in sea fish Trachinotus blochii of peak concentration (Cmax) was obtained directly in the concentration time profile; the residue levels in blood, muscle, liver, and kidney samples after 0.5 h depletion were at the maximum concentration. The Cmax in blood was determined to be 0.43 mg/mL and the half life was calculated to be 50.58 h. The Cmax in muscle was determined to be 1.43 mg/g and the half life was calculated to be 25.76 h. The Cmax in liver was determined to be 1.42 mg/g and the half life was calculated to be 45 h. The Cmax in kidney was determined to be 3.14 mg/g and the half life was calculated to be 25.76 h; Oxolinic acid in sea fish Lates calcarifer of Cmax was obtained directly in the concentration time profile; the residue levels in blood, muscle, liver, and kidney samples after 1 h depletion were at the maximum concentration. The Cmax in blood was determined to be 1.55 mg/mL and the half life was calculated to be 170.69 h. The Cmax in muscle was determined to be 2.55 mg/g and the half life was calculated to be 84.51 h. The Cmax in liver was determined to be 8.18 mg/g and the half life was calculated to be 106.61 h. The Cmax in kidney was determined to be 4.72 mg/g and the half life was calculated to be 111.77 h.
An experimental trial was performed to establish an adequate depletion period of oxolinic acid in sea fish Trachinotus blochii and Lates calcarifer of pharmacokinetic and residue studies. The pharmacokinetics of oxolinic acid was applied by oral administration at the dose of 60 mg/kg b.w./day, and was given at a daily dose for five consecutive days. A high performance liquid chromatographic method based on fluorescence detection was developed for determination of oxolinic acid in fish blood, muscle, liver and kidney. Data showed that the average residue levels in sea fish Trachinotus blochii of blood, muscle and kidney decreased to 2.74 ng/mL, 13.82 ng/g, and 21.53 ng/g after 24 days post dosing, respectively; with one exception at 195.01 ng/g in liver tissue. The present study provided data on the depletion of oxolinic acid residues in sea fish Trachinotus blochii after oral administration of five doses of the drug. The residue levels after 24 days depletion decreased to below the maximum residue limits (MRLs) after last oral treatment. At the dosage of 60 mg/kg b.w./day, we suggested that the recommended withdraw period was 36 days; Data also showed that the average residue levels in Lates calcarifer of blood muscle, liver and kidney decreased to MRLs after 2, 12, 36, and 36 days post dosing, respectively. The present study provided data on the depletion of oxolinic acid residues in Lates calcarifer after oral administration of five doses of the drug. The residue levels after 12 days depletion decreased to below the MRLs after last oral treatment. At the dosage of 60 mg/kg b.w./day, we suggested that the recommended withdraw period was 18 days.

Identiferoai:union.ndltd.org:TW/099NTU05541003
Date January 2011
CreatorsChi-Wei Kuo, 郭紀偉
ContributorsTzong-Fu Kuo, 郭宗甫
Source SetsNational Digital Library of Theses and Dissertations in Taiwan
Languagezh-TW
Detected LanguageEnglish
Type學位論文 ; thesis
Format96

Page generated in 0.0083 seconds